COLL / Collegium Pharmaceutical (COLL) Reports Q4 Loss, Lags Revenue Estimates

Today, we revisit Collegium Pharmaceutical, Inc., which has seen a 30% increase in its stock price since our last look at it in June 2022. Collegium P more_horizontal

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Neverthe more_horizontal

Collegium Pharmaceutical is a specialty pharmaceutical company focused on developing innovative treatments for chronic pain with abuse-deterrent techn more_horizontal

Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2023, it might b more_horizontal

Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Christopher James - Vice Pr more_horizontal

Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Christopher James - V more_horizontal

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 5.83% and 2%, respectively, for the quarter ended December 2022. Do the nu more_horizontal

My Collegium Pharmaceutical position has been gathering thanks to the ticker trading between my Buy and Sell Targets. The company's Q3 earnings beat h more_horizontal